EMORY UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1836-12-10

Employees: 10K

Market Cap: -

Website: http://www.emory.edu

Clinical Trials

Immunosuppression in Amyotrophic Lateral Sclerosis (ALS)

Phase 2

Completed

Conditions: Amyotrophic Lateral Sclerosis (ALS)

Interventions: Drug: Basiliximab
Drug: Methylprednisolone
Drug: Prednisone
Drug: Tacrolimus
Drug: Mycophenolate mofetil

First Posted Date: 2013-06-24

Last Posted Date: 2017-11-06

Lead Sponsor: Emory University

Target Recruit Count: 31

Registration Number: NCT01884571

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
University of Massachusetts Medical School, Worcester, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Potential Use of Indocyanine Green as a Fluorescent Agent for Definition of Surgical Margins in Cancer

Phase 1

Completed

Conditions: Malignant Neoplasm

Interventions: Drug: Indocyanine green (ICG)

First Posted Date: 2013-06-24

Last Posted Date: 2017-03-09

Lead Sponsor: Emory University

Target Recruit Count: 24

Registration Number: NCT01884584

Locations: 🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States

Comparison of Absorption of Vitamin D in Cystic Fibrosis

Phase 4

Completed

Conditions: Cystic Fibrosis

Interventions: Dietary Supplement: Vitamin D Powder
Dietary Supplement: Vitamin D Oil

First Posted Date: 2013-06-19

Last Posted Date: 2015-11-20

Lead Sponsor: Emory University

Target Recruit Count: 17

Registration Number: NCT01880346

Locations: 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States

Omacetaxine for Consolidation and Maintenance

Phase 2

Terminated

Conditions: Acute Myelogenous Leukemia (AML)

Interventions: Drug: Omacetaxine

First Posted Date: 2013-06-10

Last Posted Date: 2019-09-24

Lead Sponsor: Emory University

Target Recruit Count: 7

Registration Number: NCT01873495

Locations: 🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States

DTI of the Brain and Cervical Spine: Evaluation in Normal Subjects and Patients With Cervical Spondylotic Myelopathy

Completed

Conditions: Cervical Spondylosis With Myelopathy

First Posted Date: 2013-06-05

Last Posted Date: 2015-07-15

Lead Sponsor: Emory University

Target Recruit Count: 26

Registration Number: NCT01868958

Locations: 🇺🇸
Center for Systems Imaging (CSI), Emory University, Atlanta, Georgia, United States

Couples HIV Counseling and Testing for Male Couples in the United States

Not Applicable

Completed

Conditions: HIV

Interventions: Behavioral: Couples Voluntary HIV Counseling and Testing
Behavioral: Individual Counseling and Testing

First Posted Date: 2013-05-23

Last Posted Date: 2015-05-22

Lead Sponsor: Emory University

Target Recruit Count: 216

Registration Number: NCT01861210

Locations: 🇺🇸
AID Atlanta, Atlanta, Georgia, United States

Exparel vs. Standard Bupivicaine for Abdominoplasty

Phase 4

Terminated

Conditions: Pain, Postoperative

Interventions: Drug: Standard bupivicaine
Drug: Liposomal Injection Bupivacaine (Exparel)

First Posted Date: 2013-05-14

Last Posted Date: 2014-11-02

Lead Sponsor: Emory University

Target Recruit Count: 4

Registration Number: NCT01853176

Locations: 🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸
Emory Aesthetic Center at Paces, Atlanta, Georgia, United States
🇺🇸
Emory University Hospital, Atlanta, Georgia, United States

Living Well Project for Persons With AIDS

Not Applicable

Completed

Conditions: Acquired Immunodeficiency Syndrome (AIDS)

Interventions: Behavioral: AIDS EPC Package plus MI
Other: Standard of Care (SOC)

First Posted Date: 2013-05-07

Last Posted Date: 2019-12-30

Lead Sponsor: Emory University

Target Recruit Count: 121

Registration Number: NCT01848483

Locations: 🇺🇸
Emory University, Nell Hodgson Woodruff School of Nursing, Atlanta, Georgia, United States

Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes

Phase 4

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: Metformin and Sitagliptin
Drug: Sitagliptin
Drug: Basal Bolus
Drug: Glargine 80%
Drug: Glargine
Drug: Glargine 50%

First Posted Date: 2013-05-03

Last Posted Date: 2017-05-30

Lead Sponsor: Emory University

Target Recruit Count: 292

Registration Number: NCT01845831

Locations: 🇺🇸
Grady Memorial Hospital, Atlanta, Georgia, United States
🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸
Temple University, Philadelphia, Pennsylvania, United States

and more 2 locations

Phase Analysis and Obstructive CAD on Rubidium PET

Phase 2

Withdrawn

Conditions: Coronary Artery Disease

Interventions: Drug: Regadenoson

First Posted Date: 2013-04-26

Last Posted Date: 2014-06-02

Lead Sponsor: Emory University

Registration Number: NCT01840696

Locations: 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy